SCHEMBL742262

SCHEMBL742262

COc1cc(I)ccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.61
SLC22A6 Q4U2R8 1/20 0.53
SLC22A8 Q8TCC7 1/20 0.53
MEN1 O00255 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
TRPA1 O75762 1/20 0.52
TRIM24 O15164 1/20 0.52
ALDH1A1 P00352 1/20 0.52
HPGD P15428 1/20 0.52
ALDH5A1 P51649 1/20 0.52
ABAT P80404 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
TRIM33 Q9UPN9 1/20 0.52
HTT P42858 1/20 0.52
CXCL12 P48061 1/20 0.51
CA2 P00918 2/20 0.50
TAAR1 Q96RJ0 2/20 0.50
NR3C1 P04150 2/20 0.50
TYR P14679 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4573940 0.82 ALDH1A1 (0.52) SLC22A6SLC22A8MEN1KMT2AALDH1A1
SCHEMBL470124 0.78 CA2 (0.54) ALDH1A1CA2NR3C1TSHRMAPK1
SCHEMBL31277237 0.78 CA2 (0.54) ALDH1A1CA2NR3C1TSHRMAPK1
SCHEMBL16978291 0.77 STK17B (0.39) MAOBCXCL12CA2NR3C1TTR
SCHEMBL16978292 0.77 KCNH2 (0.42) MAOBALDH1A1HPGDTDP1CXCL12
SCHEMBL29373807 0.76 MAOB (1.00) MAOBSLC22A6SLC22A8MEN1RAB9A
SCHEMBL197234 0.76 APP (0.38) CA2TSHRLMNA
SCHEMBL3693339 0.76 MAOB (0.67) MAOBSLC22A6SLC22A8MEN1RAB9A
SCHEMBL62784 0.76 MAOB (1.00) MAOBSLC22A6SLC22A8MEN1RAB9A
SCHEMBL92236 0.74 MAOB (0.64) MAOBSLC22A6SLC22A8MEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4519340-B1 PROCESS FOR PREPARING A POLYCARBONATE BY METAL CATALYZED CROSS COUPLING COVESTRO DEUTSCHLAND AG (DE) 2026-04-01 EP disclosed
EP-4711010-A2 PRO-PERFUME COMPOSITIONS Firmenich SA (CH) 2026-03-18 EP disclosed
US-RE50800-E1 Pro-fragrance compounds FIRMENICH SA (CH) 2026-02-17 US disclosed
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD TOPAZ THERAPEUTICS INC (US) 2026-01-22 US disclosed
US-20250263631-A1 PRO-PERFUME COMPOSITIONS FIRMENICH SA (CH) 2025-08-21 US disclosed
US-12325839-B2 Pro-perfume compositions FIRMENICH SA (CH) 2025-06-10 US disclosed
WO-2025105136-A1 RESIST COMPOSITION, RESIST PATTERN FORMATION METHOD, COMPOUND, AND ACID DIFFUSION CONTROL AGENT 東京応化工業株式会社 2025-05-22 WO disclosed
EP-4519340-A1 PROCESS FOR PREPARING A POLYCARBONATE BY METAL CATALYZED CROSS COUPLING Covestro Deutschland AG (DE) 2025-03-12 EP disclosed
CN-119371290-A Method for preparing deuterated phenol by copper-supported catalysis of ETS-10 zeolite 常州大学 2025-01-28 CN disclosed
US-20250009685-A1 HYDROXYPHENYL-ETHYNYL-PHENOL DERIVATIVES AS AR (ANDROGEN RECEPTOR) TRANSCRIPTIONAL ACTIVITY MODULATORS FOR USE IN THE TREATMENT OF I.A. PROSTATE CANCER FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) 2025-01-09 US disclosed
WO-2004069774-A2 SYNTHESIS OF 13C-LABELLED ESTROGEN ANALOGUES THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2004-08-19 WO disclosed
US-6479491-B1 USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, ESPECIALLY PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA NEUROSEARCH A/S (DK) 2002-11-12 US disclosed
US-6207662-B1 USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA NEUROSEARCH A/S (DK) 2001-03-27 US disclosed
EP-0920423-A1 DISUBSTITUTED MORPHOLINE, OXAZEPINE OR THIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D4 RECEPTOR ANTAGONISTS NEUROSEARCH A/S (DK) 1999-06-09 EP disclosed
WO-1998007710-A1 DISUBSTITUTED MORPHOLINE, OXAZEPINE OR THIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D4 RECEPTOR ANTAGONISTS NEUROSEARCH A/S (DK) 1998-02-26 WO disclosed
EP-0287909-B1 AMYLOIDOSIS AND ALZHEIMER'S DISEASE DIAGNOSTIC ASSAY AND REAGENTS THEREFOR SALUTAR, INC. (US) 1992-09-02 EP disclosed
US-5039511-A Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor SALUTAR, INC. (US) 1991-08-13 US disclosed
US-5008099-A Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor SALUTAR, INC. (US) 1991-04-16 US disclosed
US-4933156-A Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor SALUTAR, INC. (US) 1990-06-12 US disclosed
EP-0287909-A1 Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor SALUTAR, INC. (US) 1988-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250009685-A1 HYDROXYPHENYL-ETHYNYL-PHENOL DERIVATIVES AS AR (ANDROGEN RECEPTOR) TRANSCRIPTIONAL ACTIVITY MODULATORS FOR USE IN THE TREATMENT OF I.A. PROSTATE CANCER AR, NCOA1, NR5A1 MAOB 1864/4885SLC22A6 2245/4885SLC22A8 2687/4885
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD RIOX2, ORC3, DCLRE1A MAOB 3262/4885SLC22A6 3484/4885SLC22A8 3690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.